Commentary

Video

Dr. Goswami's Oncology Journey: Patient-centric Science and Mentorship Stories

Author(s):

Sangeeta Goswami, MD, PhD

Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.

Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.

Related Videos
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Sam Brondfield, MD, MA
Salman R. Punekar, MD
Naval G. Daver, MD
Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Elias Jabbour, MD,
Ibrahim T. Aldoss, MD
Related Content
V. Craig Jordan, PhD
July 22nd 2024

V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76

Robert Z. Orlowski, MD, PhD, Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma, director, Section of Myeloma, professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
July 11th 2024

Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

Michael Wang, MD, professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
July 18th 2024

Ibrutinib Plus Venetoclax Generates Durable CRs in TP53+ Mantle Cell Lymphoma

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.
July 14th 2024

FDA Awards Fast Track Designation to CT-0525 for HER2-Overexpressing Solid Tumors

Vivek Subbiah, MD, chief, early-phase drug development, Sarah Cannon Research Institute
July 11th 2024

Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies